Использование публичных данных в судебных экспертизах по определению стоимости объектов недвижимости: проблемы, ограничения, возможности

One of the problems with the practice of legal proceedings is the determination of the legal authority limits of a forensic expert when he forms an array of initial data, the structure and content of which would provide a full and comprehensive research of the issues put before him by the body (person) having appointed the examination. The possibility of the specifed initial data completeness ensuring is suggested and substantiated in the article, arguments arising from the provisions of the law concerning neutralization of the traditional criticism directions of the expert in this part during his interrogation in the course of judicial proceedings on his conclusion are adduced.Одна из проблем судопроизводства – определение пределов правомочий судебного эксперта при формировании им массива исходных данных, структура и содержание которого обеспечивала бы полное и всестороннее исследование по вопросам, поставленным перед ним органом (лицом), назначившим экспертизу. В статье предложена и обоснована возможность обеспечения полноты указанных исходных данных, приведены вытекающие из положений закона аргументы относительно нейтрализации традиционных направлений критики эксперта в этой части при его допросе в ходе судебного заседания по данному им заключению

МЕТОДОЛОГИЧЕСКИЙ ПОДХОД К ПЛАНИРОВАНИЮ ЭКСПЕРИМЕНТА ПРИ ВЫБОРЕ КАЧЕСТВЕННЫХ РЕАКЦИЙ ДЛЯ ПОДТВЕРЖДЕНИЯ ПОДЛИННОСТИ КОМПОНЕНТОВ ЛЕКАРСТВЕННОГО СРЕДСТВА (НА ПРИМЕРЕ АСКОРБИНОВОЙ КИСЛОТЫ)

The need for identification  testing of active substances or excipients in multi-component medicinal products,  including the use of qualitative tests, calls for research substantiating the choice of tests and test conditions  with due regard to interference  effects caused by other components  of medicinal products and the amount of the sample used. The aim of the study was to develop a methodological approach to designing experiments while selecting qualitative reactions for identification testing of a medicinal product component based on the results of studies investigating the possibility of using known qualitative tests (as illustrated by ascorbic acid in a multi-component product — 0.4 mg of ascorbic acid per 100 mg of the vial contents)  with due regard to interference on the part of other medicinal product components and the amount of the sample used. Material and methods: the study focused on a multi-component medicinal product — lyophilisate for solution for intravenous and intramuscular  injections containing an antiinflammatory active substance and ascorbic acid as a stabilizing agent (antioxidant). The analysis of literature sources helped to determine qualitative tests that were assessed for potential use for identification testing of ascorbic acid as a component of the analysed medicinal product. The study involved experimental testing of the qualitative reactions based on acidic and reducing properties of ascorbic acid. Results: it was demonstrated that several well-known qualitative tests could be used for identification  testing of ascorbic acid as a component of the analysed medicinal product,  namely, the reaction of ferrous ascorbate formation  and the reaction of silver nitrate reduction to metallic silver after preliminary separation of ascorbic acid from the other medicinal product components, as well as the reaction of Prussian blue formation,  iodine test and reaction with a potassium permanganate solution, which do not require additional sample preparation.  It is not practicable to use the reaction with a methylene blue solution and the Fehling’s reagent reaction for this particular medicinal product,  since their results are feeble. Conclusions: the analysis of the multi-component medicinal product helped to develop a methodological  approach to choosing qualitative reactions for identification testing of one of the medicinal product’s components  (e.g., ascorbic acid). The suggested algorithm includes the choice of reactions, determination of their sensitivity and applicability for a particular medicinal product, analysis of the other components’ effects on the results of the chemical reaction,  and the need for additional sample preparation.  The whole complex of the studies performed helped to determine qualitative reactions and optimal conditions for identification testing of the analysed substance.Необходимость подтверждения подлинности  действующих  или  вспомогательных веществ  многокомпонентных лекарственных средств,  в том числе с использованием качественных  реакций, влечет за собой  необходимость  проведения исследований по выбору реакций  и условий их проведения с учетом мешающего  влияния других компонентов лекарственного средства  и количества  используемого образца.  Цель работы: разработка  методологического подхода к планированию эксперимента при выборе  качественных  реакций  для подтверждения подлинности определяемого компонента лекарственного средства на основании результатов исследований возможности использования известных качественных  реакций  (на примере  аскорбиновой кислоты  в многокомпонентном лекарственном средстве — 0,4 мг аскорбиновой кислоты / 100 мг содержимого  флакона) с учетом мешающего влияния других компонентов лекарственного средства и количества  используемого образца.  Материалы и методы: в качестве  объекта исследования было выбрано  многокомпонентное лекарственное средство  — лиофилизат для приготовления раствора  для внутривенного и внутримышечного введения  с лекарственным веществом,  обладающим  противовоспалительным действием,  в состав которого  входит аскорбиновая кислота  в качестве  стабилизатора (антиоксиданта). В результате анализа  данных литературы  выбраны  качественные реакции  для проведения исследований возможности их использования для подтверждения  подлинности аскорбиновой кислоты  в изучаемом  лекарственном средстве.  Проведена  экспериментальная проверка  реакций, основанных на кислотных  и восстановительных свойствах аскорбиновой кислоты.  Результаты: установлено, что в изучаемом многокомпонентном лекарственном средстве для подтверждения подлинности аскорбиновой кислоты могут быть применимы несколько известных качественных реакций: реакции образования аскорбината железа и восстановления нитрата серебра до металлического серебра после предварительного отделения аскорбиновой кислоты  от других компонентов лекарственного средства,  а также реакция  образования берлинской лазури,  йодная проба и реакция  с раствором  перманганата калия,  не требующие  дополнительной пробоподготовки. Использование реакций  с раствором  метиленового  синего и реактивом  Фелинга  применительно к данному лекарственному средству нецелесообразно, так как результат указанных реакций  слабо выражен. Выводы: на примере многокомпонентного лекарственного средства разработан  методологический подход к выбору качественных  реакций  для подтверждения подлинности одного  из компонентов лекарственного средства  (например, аскорбиновой кислоты).  Алгоритм действий включает в себя выбор реакций, определение их чувствительности и целесообразности применения для конкретного лекарственного средства,  изучение  влияния других его компонентов на результат химической реакции, а также необходимость  или отсутствие дополнительной пробоподготовки. Совокупность проведенных  исследований позволяет сделать выбор качественных  реакций  и оптимальных  условий  их проведения для достижения поставленной цели — подтверждения подлинности определяемого вещества

DIABETES MELLITUS IN NEUROENDOCRINE DISEASES

There are many endocrine diseases accompanied by development of secondary diabetes mellitus (sDM). The features of the development and course of sDM in acromegaly, Cushing’s syndrome, and growth hormone (GH) deficiency are of particular interest as the prevalence of sDM associated with these pathologies is higher than that in the population. The main risk factors for sDM in acromegaly are age, female gender, arterial hypertension, family history of type 2 DM (T2DM), acromegaly activity, and duration and certain treatment methods of acromegaly. The differences of the sDM pathogenesis from pathogenesis of T2DM in the population are due to the opposite effect of GH and insulin-like growth factor 1 on glucose metabolism as well as to effect of acromegaly treatment on the mechanisms of diabetes development. The prevalence of diabetes in patients with GH deficiency, especially against the background of GH replacement therapy, is slightly higher than that in population. However, some studies have shown that GH replacement therapy may lead to normalization of the impaired glucose metabolism. High prevalence of metabolic syndrome (43%) and visceral obesity in the GH deficiency are the causes of the development of lipotoxicity (free fatty acids excess) and insulin resistance.In Cushing’s syndrome, the prevalence of early carbohydrate metabolism disturbances may reach 70%. In Cushing’s disease, chronic glucocorticoid excess determines insulin resistance and reduces insulin secretion, which results in hyperglycaemia. Currently, the recommendations for the treatment of sDM in acromegaly, hypercortisolism, and GH deficiency are the same as for the treatment of T2DM. However, as the pathogenesis is different in sDM and T2DM, the new algorithms for the diagnosis, prevention and treatment need to be developed. Prevention and timely treatment based on pathological principals will slow down the development of micro- and macrovascular complications leading to early disability and death of patients with neuroendocrine diseases

The Application of Public Data in Forensic Real Estate Valuations: Problems, Limitations, Opportunities

One of the problems with the practice of legal proceedings is the determination of the legal authority limits of a forensic expert when he forms an array of initial data, the structure and content of which would provide a full and comprehensive research of the issues put before him by the body (person) having appointed the examination. The possibility of the specifed initial data completeness ensuring is suggested and substantiated in the article, arguments arising from the provisions of the law concerning neutralization of the traditional criticism directions of the expert in this part during his interrogation in the course of judicial proceedings on his conclusion are adduced

A METHODOLOGICAL APPROACH TO DESIGNING EXPERIMENTS WHEN DEALING WITH IDENTIFICATION TESTS FOR MEDICINAL PRODUCT COMPONENTS (AS ILLUSTRATED BY ASCORBIC ACID)

The need for identification  testing of active substances or excipients in multi-component medicinal products,  including the use of qualitative tests, calls for research substantiating the choice of tests and test conditions  with due regard to interference  effects caused by other components  of medicinal products and the amount of the sample used. The aim of the study was to develop a methodological approach to designing experiments while selecting qualitative reactions for identification testing of a medicinal product component based on the results of studies investigating the possibility of using known qualitative tests (as illustrated by ascorbic acid in a multi-component product — 0.4 mg of ascorbic acid per 100 mg of the vial contents)  with due regard to interference on the part of other medicinal product components and the amount of the sample used. Material and methods: the study focused on a multi-component medicinal product — lyophilisate for solution for intravenous and intramuscular  injections containing an antiinflammatory active substance and ascorbic acid as a stabilizing agent (antioxidant). The analysis of literature sources helped to determine qualitative tests that were assessed for potential use for identification testing of ascorbic acid as a component of the analysed medicinal product. The study involved experimental testing of the qualitative reactions based on acidic and reducing properties of ascorbic acid. Results: it was demonstrated that several well-known qualitative tests could be used for identification  testing of ascorbic acid as a component of the analysed medicinal product,  namely, the reaction of ferrous ascorbate formation  and the reaction of silver nitrate reduction to metallic silver after preliminary separation of ascorbic acid from the other medicinal product components, as well as the reaction of Prussian blue formation,  iodine test and reaction with a potassium permanganate solution, which do not require additional sample preparation.  It is not practicable to use the reaction with a methylene blue solution and the Fehling’s reagent reaction for this particular medicinal product,  since their results are feeble. Conclusions: the analysis of the multi-component medicinal product helped to develop a methodological  approach to choosing qualitative reactions for identification testing of one of the medicinal product’s components  (e.g., ascorbic acid). The suggested algorithm includes the choice of reactions, determination of their sensitivity and applicability for a particular medicinal product, analysis of the other components’ effects on the results of the chemical reaction,  and the need for additional sample preparation.  The whole complex of the studies performed helped to determine qualitative reactions and optimal conditions for identification testing of the analysed substance